ABSTRACT
A molecular variant of human serum thyroxine-binding globulin (TBG), containing only triantennary oligosaccharide chains and having a more prolonged in vivo survival (TBG-1), was first detected in normal pregnancy and then in the postpartum period. Serum TBG-1 was measured in normal and in some pathological conditions associated with normal or increased TBG biosynthesis using a combination of Con A-Sepharose 4B microcolumn affinity chromatography and a highly sensitive TBG radioimmunoassay. TBG-1 was shown to be present in the sera of healthy subjects (0.21 +/- 0.04 micrograms/ml, n = 60; 1.15% of total TBG). The proportion of TBG-1 in total serum TBG was significantly increased (up to 9.5%) in conditions with serum TBG excess (cancer, hypothyroidism and liver diseases). It has been assumed that a selective enhancement of biosynthesis of the TBG molecular variant with a prolonged half-life in the circulation during the posttranslational modification of the polypeptide chain is a response to the body requirements in a high TBG concentration.
Subject(s)
Pregnancy Complications/blood , Pregnancy/blood , Thyroxine-Binding Proteins/chemistry , Female , Half-Life , Humans , Male , Protein Processing, Post-Translational/physiology , Reference Values , Thyroxine-Binding Proteins/metabolismABSTRACT
The results of the investigations of ACTH, HGH, hydrocortisone, glucagon, C-peptide, insulin in 180 patients with advanced and metastatic melanomas, soft tissue sarcomas, lung cancers and renal cell carcinomas testify to the development of the syndrome of endocrine hyperfunction in patients under whole-body guided hyperthermia as well as of functional pancreas insufficiency. The data presented form a biochemical basis for working out measures to optimally carry out whole-body hyperthermia treatment, aimed at increasing the range of indications for its use in clinical oncology.
